Drug Abuse Sciences
DrugAbuse Sciences (DAS) is a private, specialty pharmaceutical company dedicated to improving the treatment of alcohol and substance abuse and dependence. It focuses on discovering, developing, and commercializing medications for addiction treatment, with a mission to provide innovative and cost-effective solutions. DAS is engaged in research and development of medications targeting neurochemical pathways involved in addiction, with a portfolio that includes long-acting injectable formulations and other drug candidates. The company emphasizes a combination approach of psychotherapy and medication for addiction treatment and is actively seeking partnerships and licensing opportunities worldwide.
Industries
Products
Monthly extended‑release injectable naltrexone (depot formulation)
A long‑acting injectable formulation of naltrexone designed for once‑monthly intramuscular administration to reduce relapse in alcohol dependence; progressed to Phase III clinical trials.
Long‑acting naltrexone injectable for opioid dependence
A naltrexone injectable suspension developed for opiate dependence intended for monthly administration; Phase IIb data reported and a Phase III trial planned in a probationer population.
D1 receptor agonist for CNS indications (receptor‑targeted small molecule)
Development and clinical evaluation of a dopamine D1 receptor agonist for cognitive impairment and addiction indications; prior Phase II testing completed in cocaine‑dependent patients.
Long‑acting buprenorphine depot formulation
Preclinical development of an extended‑release injectable buprenorphine formulation intended for once every 4–6 week administration using a microsphere depot platform.
Antibody antidote for cocaine overdose (equine F(ab')2‑based)
A biologic antidote intended for emergency treatment of cocaine overdose; developed as an equine F(ab')2 antibody construct and manufactured under an exclusive agreement with an external biologics manufacturer.
LACTIZ extended‑release drug delivery platform
A platform technology combining drug with a poly(D,L‑lactide) polymer matrix to produce microspheres that can be formulated into intramuscular suspensions for extended release over variable durations.
Monthly extended‑release injectable naltrexone (depot formulation)
A long‑acting injectable formulation of naltrexone designed for once‑monthly intramuscular administration to reduce relapse in alcohol dependence; progressed to Phase III clinical trials.
Long‑acting naltrexone injectable for opioid dependence
A naltrexone injectable suspension developed for opiate dependence intended for monthly administration; Phase IIb data reported and a Phase III trial planned in a probationer population.
D1 receptor agonist for CNS indications (receptor‑targeted small molecule)
Development and clinical evaluation of a dopamine D1 receptor agonist for cognitive impairment and addiction indications; prior Phase II testing completed in cocaine‑dependent patients.
Long‑acting buprenorphine depot formulation
Preclinical development of an extended‑release injectable buprenorphine formulation intended for once every 4–6 week administration using a microsphere depot platform.
Antibody antidote for cocaine overdose (equine F(ab')2‑based)
A biologic antidote intended for emergency treatment of cocaine overdose; developed as an equine F(ab')2 antibody construct and manufactured under an exclusive agreement with an external biologics manufacturer.
LACTIZ extended‑release drug delivery platform
A platform technology combining drug with a poly(D,L‑lactide) polymer matrix to produce microspheres that can be formulated into intramuscular suspensions for extended release over variable durations.
Services
Licensing and partnership development
Sourcing and offering licensing opportunities for drug candidates and drug delivery technologies, and establishing regional commercial partnerships for product distribution.
Clinical development and trial sponsorship for addiction therapeutics
Sponsorship and management of Phase II and Phase III clinical trials for addiction and related CNS indications.
Licensing and partnership development
Sourcing and offering licensing opportunities for drug candidates and drug delivery technologies, and establishing regional commercial partnerships for product distribution.
Clinical development and trial sponsorship for addiction therapeutics
Sponsorship and management of Phase II and Phase III clinical trials for addiction and related CNS indications.
Expertise Areas
- Addiction medicine drug development
- Extended‑release depot formulation development
- Antibody therapeutics for overdose
- Clinical trial management for CNS/addiction indications (Phase II–III)
Key Technologies
- Poly(D,L‑lactide) microsphere sustained‑release injectables
- Microencapsulation for sustained drug delivery
- Depot injectable formulation platforms
- Polyclonal and monoclonal antibody therapeutics